OmegaQuant’s Omega-3 Index and Prenatal DHA test kits are now registered in the European Union as in vitro medical devices and CE-marked.
OmegaQuant’s Omega-3 Index and Prenatal DHA test kits are now registered in the European Union as in vitro medical devices and CE-marked, demonstrating that it meets the essential requirements of all relevant European Medical Device Directives. This means that the kits now meet regulatory approval for sale in Europe. To carry out analysis of omega-3 test coming from European consumers, OmegaQuant has partnered with the Nutritional Analytical Service at the Institute of Aquaculture at the University of Stirling, in Scotland.
“We are partnering with the University of Stirling to run our testing methods in their laboratory,” explains Jason Polreis, CEO, OmegaQuant, in a press release. “This way we are offering the same accurate, precise, and scientifically validated methods at our three laboratories covering North America, Asia-Pacific, and now Europe.”
Having a dedicated lab in Europe allows OmegaQuant to deliver results in a timelier manner. “We are looking forward to bringing an at-home collection kit to the EU market to make access to the Omega-3 Index and Prenatal DHA tests convenient, so individuals can personalize their omega-3 intake,” adds Polreis.